Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001689375-25-000024
Filing Date
2025-05-08
Accepted
2025-05-08 07:09:25
Documents
72
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q trda-20250331.htm   iXBRL 10-Q 1399483
2 EX-31.1 trda-20250331x10qex311.htm EX-31.1 10861
3 EX-31.2 trda-20250331x10qex312.htm EX-31.2 10884
4 EX-32.1 trda-20250331x10qex321.htm EX-32.1 7212
  Complete submission text file 0001689375-25-000024.txt   5956316

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trda-20250331.xsd EX-101.SCH 35349
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT trda-20250331_cal.xml EX-101.CAL 58406
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT trda-20250331_def.xml EX-101.DEF 168445
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trda-20250331_lab.xml EX-101.LAB 527045
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trda-20250331_pre.xml EX-101.PRE 364670
75 EXTRACTED XBRL INSTANCE DOCUMENT trda-20250331_htm.xml XML 631376
Mailing Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210
Business Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210 857-305-1825
Entrada Therapeutics, Inc. (Filer) CIK: 0001689375 (see all company filings)

EIN.: 813983399 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40969 | Film No.: 25923825
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)